A clinical trial [207] evaluating the administration of capivasertib (an Akt inhibitor) in combination with fulvestrant in patients with ER-positive, HER2-negative breast cancer, with or without prior or ongoing treatment with CDK4/6 inhibitors, demonstrated a significant improvement in PFS. The gene discussed is AKT1; the disease is breast carcinoma.